Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Delaware for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Delaware only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Delaware (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Accredo Health Group Inc (NPI 1538281837)

Field	Value
Entity Type	Organization
Organization	Accredo Health Group Inc
Address	2051 Old Coochs Bridge Rd Ste 100
City	Newark
State	DE
ZIP	19702
Taxonomy	Pharmacy
NPI Enumerated	April 6, 2007

Payer Source	Total Paid
Medicaid	$10.2M
Medicare	$0

Key Findings

This provider is effectively a Medicaid-focused operation: it has no Medicare billing on file and reports total Medicaid revenue of $10.2M. The absence of Medicare activity combined with the Medicaid revenue scale indicates a single-payer (Medicaid) business footprint for its billed services.

Revenue is highly concentrated in just a few high-cost injectable products: the precomputed top 3 Medicaid codes account for 94.2% of the provider's total Medicaid revenue. Specifically, J2357 generates $5.6M (55.3% of Medicaid revenue), J0585 generates $3.4M (33.2%), and 90378 generates $585.7K (5.7%), together composing the overwhelming majority of reported Medicaid receipts.

The provider’s taxonomy (Pharmacy) plus the billed codes point to a specialty pharmacy or outpatient injectable/biologics dispensing operation rather than routine retail pharmacy services. The dominant codes—omalizumab (J2357), onabotulinumtoxina (J0585), and immune globulin (90378)—are specialty, clinician-administered or pharmacy-dispensed biologics and high-cost injectables, indicating the business is centered on high-acuity, specialty medication supply and administration.

J2357 is the single largest revenue driver at $5.6M (55.3% of Medicaid revenue) and is listed as rank #1 of 1 providers in-state with no state peer volume comparison available; this suggests the provider is the sole in-state filer for omalizumab in the dataset and therefore occupies a unique or non-competed position for this product in the state data. That sole-reporter status should be interpreted as a lack of available state peer volume comparison rather than a quantified market share against competitors.

For J0585 (onabotulinumtoxina), the provider reports $3.4M (33.2% of Medicaid revenue) but ranks #3 of 4 providers in-state and is labeled as 33th percentile with a 'typical, unremarkable volume for this code.' This indicates the provider is a modest participant for onabotulinumtoxina relative to in-state peers despite the large absolute revenue contribution to its own Medicaid totals.

90378 (RSV–IgIM) contributes $585.7K (5.7% of Medicaid revenue) and is also ranked #1 of 1 providers in-state with no state peer volume comparison available, highlighting another code where the provider appears as the sole in-state reporter in the dataset. The presence of RSV immune globulin alongside larger biologic lines underscores a portfolio focused on specialized immunologic products and niche therapeutic areas.

The provider also bills Sublocade codes Q9992 ($254.9K, 2.5% of Medicaid revenue) and Q9991 ($170.1K, 1.7%), each ranked #1 of 1 providers in-state with no state peer volume comparison available; this shows the business includes extended‑release buprenorphine administration in its service mix. Although these codes are smaller revenue contributors, their presence signals involvement in medication-assisted treatment modalities alongside other specialty injectables.

The NPI was enumerated on 2007-04-06 (~19 years ago), indicating it is an established entity; combined with the concentrated catalog of specialty injectable codes, this suggests a stable, long-running specialty pharmacy or injectable-dispensing operation. However, the extreme revenue concentration in a handful of codes implies operational and reimbursement risk if payer coverage or supply for those specific biologics changes, and the lack of Medicare billing means competitive dynamics will be driven primarily by Medicaid policies and state-level peers.

Medicaid: Complete Services Breakdown

Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.

7 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2357	Injection, omalizumab, 5 mg	2,510	$2,250	$5.6M
J0585	Injection, onabotulinumtoxina, 1 unit	3,170	$1,070	$3.4M
90378	Immunoglobulin is a very complex protein that is produced by certain cells in the body to protect it from various types of infections and produce passive immunity. RSV–IgIM (respiratory syncytial…	160	$3,640	$585.7K
Q9992	Injection, buprenorphine extended-release (sublocade), greater than 100 mg	150	$1,660	$254.9K
Q9991	Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg	100	$1,700	$170.1K
J0897	Injection, denosumab, 1 mg	70	$1,360	$96.6K
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	60	$1,150	$68K

Medicaid: Competitive Analysis & Benchmarks

How this provider's Medicaid billing volume and revenue compare to other Delaware providers billing the same CPT/HCPCS codes.

Claims Volume vs. Delaware Distribution

Accredo Health Group Inc — 0 of 7 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Delaware

Full comparison — all codes billed, vs. Delaware median

7 rows

CPT/HCPCS Code	Description	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2357	Injection, omalizumab, 5 mg	1	10	2,510	$2,250	$5.6M
J0585	Injection, onabotulinumtoxina, 1 unit	3	10	3,180	$480	$1.4M
90378	Immunoglobulin is a very complex protein that is produced by certain cells in the body to protect it from various types of infections and produce passive immunity. RSV–IgIM (respiratory syncytial…	1	10	160	$3,640	$585.7K
Q9992	Injection, buprenorphine extended-release (sublocade), greater than 100 mg	1	10	150	$1,660	$254.9K
Q9991	Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg	1	10	100	$1,700	$170.1K
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	7	10	110	$540	$96.5K
J0897	Injection, denosumab, 1 mg	3	10	70	$980	$77.4K

Related Providers

Other providers that share a Tax Identification Number (TIN) with Accredo Health Group Inc, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Accredo Health Group Inc	PA	Pharmacy	$37.8M	$130.9M
Accredo Health Group Inc	TN	Pharmacy	$0	$165.6M
Accredo Health Group Inc	TX	Pharmacy	$0	$27.7M
Accredo Health Group Inc	FL	Specialty Pharmacy	$10.5K	$18.1M
Accredo Health Group Inc	AZ	Pharmacy	$65.5K	$9.1M
Accredo Health Group Inc	KS	Pharmacy	$0	$944.9K
Accredo Health Group Inc	HI	Pharmacy	$0	$549.1K

Nearby Providers

Other providers in the same ZIP code as Accredo Health Group Inc, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mosaic	DE	Mental Illness Community Based Residential Treatment Facility	$0	$118.5M
Community Systems, Inc.	DE	Intellectual & Developmental Disabilities Psychologist	$0	$96.7M
Resources For Human Development Inc.	DE	Intellectual & Developmental Disabilities Psychologist	$0	$86M
Epic Health Services (de), LLC	DE	Home Health Agency	$0	$33.7M
Jay J Harris Dmd PC	DE	Dentist	$0	$16.7M
Elite Home Health Care Inc	DE	In Home Supportive Care Agency	$0	$14.8M
Bear-glasgow Dental, LLC	DE	General Practice Dentistry	$0	$8.2M
Center For Child Development, Incorporated	DE	Psychologist	$0	$4.9M
Comfort Care At Home, Inc.	DE	Home Health Agency	$0	$4M
Collins Dental LLC	DE	Dentist	$0	$2.9M

Accredo Health Group Inc — Billing Profile & Reimbursement Data

Sign up for Accredo Health Group Inc — Billing Profile & Reimbursement Data policy alerts

Accredo Health Group Inc — Billing Profile & Reimbursement Data

Sign up for Accredo Health Group Inc — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicaid: Total Revenue Breakdown by CPT/HCPCS Code

Medicaid: Complete Services Breakdown

Medicaid: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References